| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.6 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.6 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.6 |